Search This Blog

Sunday, June 22, 2025

Novo Nordisk A/S: Mim8 prophylaxis treatment well-tolerated in haemophilia A in new phase 3

 

  • New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors1.

  • Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk1.

  • FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system2.

  • These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.